**Amendments to the Claims:**

Each of claims 17 through 27, 29 through 31, 33 through 41, and 49 through 53 has been amended herein. This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1 through 16 (cancelled)

17. (currently amended) A formulation comprising:

a) at least one beneficial agent, and

b) a non-aqueous, ~~single phase~~single-phase biocompatible vehicle comprising a solvent, a surfactant, and a polymer, wherein the solvent is ~~a~~ lauryl ~~alcohol~~ lactate and the solvent, surfactant, and polymer are selected and formulated such that the vehicle exhibits a viscosity capable of suspending the at least one beneficial agent.

18. (currently amended) A non-aqueous formulation comprising at least one beneficial agent uniformly suspended in a vehicle comprising a solvent, a surfactant, and a polymer, wherein the solvent is lauryl ~~alcohol~~ lactate and the solvent, surfactant and polymer are selected and formulated such that the vehicle is a non-aqueous, ~~single phase~~single-phase biocompatible vehicle that exhibits a viscosity capable of suspending the at least one beneficial agent.

19. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated such that the formulation is stable at body temperature for extended periods of time.

20. (currently amended) The formulation of claim 17, ~~which~~ wherein the at least one beneficial agent comprises at least about 0.1% (w/w) ~~beneficial agent~~ of the formulation.

21. (currently amended) The formulation of claim 17, ~~which~~ wherein the at least one beneficial agent comprises at least about 10% (w/w) ~~beneficial agent~~of the formulation.

22. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent is selected from ~~a~~ the group consisting of peptides, proteins, nucleotides, hormones, viruses, and antibodies.

23. (currently amended) The formulation of claim 22, wherein ~~said~~ the at least one beneficial agent is a protein.

24. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated ~~to provide a~~such that the formulation ~~which~~ is stable at 65° C for at least about ~~2~~ two months.

25. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated ~~to provide a~~such that the formulation ~~which~~ is stable at 37° C for at least about ~~3~~ three months.

26. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated ~~to provide a~~such that the formulation ~~which~~ is stable at 37° C for at least about one year.

27. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated ~~to provide a~~such that the formulation is adapted for use in an implantable drug delivery device.

Claim 28 (cancelled)

29. (currently amended) The formulation of claim 17, wherein ~~said~~ the non-aqueous, single-phase biocompatible vehicle comprises an antioxidant.

30. (currently amended) The formulation of claim 17, wherein the at least one beneficial agent comprises a beneficial agent which has been dried to a low moisture content prior to incorporation in ~~said~~ the formulation.

31. (currently amended) The formulation of claim 17, wherein ~~said~~ the at least one beneficial agent and ~~said~~ the non-aqueous, single-phase biocompatible vehicle are selected and formulated ~~to provide a~~such that the formulation ~~which~~ is stable after sterilization.

Claim 32 (cancelled)

33. (currently amended) A method for preparing ~~the stable~~a formulation ~~of claim 17~~ comprising at least one beneficial agent and a non-aqueous, single-phase biocompatible vehicle comprising a solvent, a surfactant, and polymer, wherein the solvent is lauryl lactate and the solvent, surfactant, and polymer are selected and formulated such that the vehicle exhibits a viscosity capable of suspending the at least one beneficial agent, the method comprising:

preparing a substantially uniform suspension of the at least one beneficial agent by combining the vehicle and the at least one beneficial agent under dry conditions, under vacuum and at elevated temperature; and

allowing the suspension to cool to room temperature.

34. (currently amended) The method of claim 33, wherein ~~uniformly suspending~~preparing a substantially uniform suspension of the at least one beneficial agent ~~in the vehicle~~ comprises preparing a substantially uniform suspension having ~~uniformly suspending~~ at least about 0.1% (w/w) beneficial agent ~~in the vehicle~~.

35. (currently amended) The method of claim 33, wherein ~~uniformly suspending~~ preparing a substantially uniform suspension of the at least one beneficial agent ~~in the vehicle~~ comprises preparing a substantially uniform suspension having ~~uniformly suspending~~ at least about 10% (w/w) beneficial agent ~~in the vehicle~~.

36. (currently amended) A method for treating a subject suffering from a condition which may be alleviated by administration of a beneficial agent comprising administering to ~~said~~ the subject a therapeutically effective amount of a formulation comprising:

a) at least one beneficial ~~agent,~~ agent; and

b) a non-aqueous, ~~single phase~~single-phase biocompatible vehicle comprising a solvent, a surfactant, and a polymer, wherein the solvent is ~~a~~ lauryl ~~alcohol~~ lactate and the solvent, surfactant, and polymer are selected and formulated such that the vehicle exhibits a viscosity capable of suspending the at least one beneficial agent.

37. (currently amended) The method of claim 36, wherein ~~said method~~administering to the subject a therapeutically effective amount of the formulation comprises parenterally administering to ~~said~~ the subject a therapeutically effective amount of ~~said~~ the formulation.

38. (currently amended) The method of claim 36, wherein ~~said method~~administering to the subject a therapeutically effective amount of the formulation comprises administering ~~said~~ the formulation to ~~said~~ the subject continuously over a ~~long term~~long term.

39. (currently amended) The method of claim 36, wherein ~~said method~~administering to the subject a therapeutically effective amount of the formulation comprises administering ~~said~~ the formulation to ~~said~~ the subject from an implantable drug delivery system.

40. (currently amended) The method of claim 36, wherein ~~said method~~administering to the subject a therapeutically effective amount of the formulation comprises administering ~~said~~ the formulation to ~~said~~ the subject daily for a period of time selected from the group consisting of about ~~3~~ three months, about ~~6~~ six months, ~~or~~ and about ~~12~~ twelve months.

41. (currently amended) The method of claim 40, wherein ~~said method~~administering to the subject a therapeutically effective amount of the formulation comprises administering ~~said~~ the formulation to ~~said~~ the subject from an implantable drug delivery system.

Claims 42 through 48 (cancelled)

49. (currently amended) The formulation of claim 17, wherein the non-aqueous, single-phase biocompatible vehicle comprises about 30% to about 50% solvent, about 5% to about 20% surfactant, and about 5% to about 60% polymer.

50. (currently amended) The formulation of claim 17, wherein the polymer is polyvinylpyrrolidone~~,~~ and the surfactant is polysorbate~~, and the solvent is lauryl lactate~~.

51. (currently amended) The formulation of claim 17, wherein the polymer is polyvinylpyrrolidone~~,~~ and the surfactant is ~~gml, and the solvent is lauryl lactate~~glycerol monolaurate.

52. (currently amended) The formulation of claim 17, wherein the ~~vehicle includes a~~ surfactant is selected from ~~a~~ the group consisting of esters of polyhydric alcohols, ethoxylated castor oil, polysorbates, esters or ethers of saturated alcohols, and polyoxyethylenepolyoxypropylene block copolymers.

53. (currently amended) The formulation of claim 17, wherein the ~~vehicle includes a~~ polymer is selected from ~~a~~ the group consisting of polyesters, pyrrolidones, esters or ethers of unsaturated alcohols, and polyoxyethylenepolyoxypropylene block copolymers.